BioMarin/$BMRN
1D1W1MYTD1Y5YMAX
Capital at risk
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
- Ticker
- $BMRN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,221
- Headquarters
- San Rafael, United States
- Website
- www.biomarin.com
BioMarin Metrics
BasicAdvanced
$12B
168.71
$0.38
0.23
-
Price and volume
Market cap
$12B
Beta
0.23
52-week high
$70.98
52-week low
$49.26
Average daily volume
2.2M
Financial strength
Current ratio
2.387
Quick ratio
1.163
Long term debt to equity
0.558
Total debt to equity
0.665
Interest coverage (TTM)
5.98%
Profitability
EBITDA (TTM)
645.319
Gross margin (TTM)
50.97%
Net profit margin (TTM)
2.14%
Operating margin (TTM)
14.67%
Effective tax rate (TTM)
51.06%
Revenue per employee (TTM)
$1,060,000
Management effectiveness
Return on assets (TTM)
3.26%
Return on equity (TTM)
1.18%
Valuation
Price to earnings (TTM)
168.715
Price to revenue (TTM)
3.614
Price to book
1.96
Price to tangible book (TTM)
15.73
Price to free cash flow (TTM)
16.979
Free cash flow yield (TTM)
5.89%
Free cash flow per share (TTM)
3.766
Growth
Revenue change (TTM)
11.20%
Earnings per share change (TTM)
-88.85%
3-year revenue growth (CAGR)
15.09%
10-year revenue growth (CAGR)
13.34%
3-year earnings per share growth (CAGR)
-10.29%
10-year earnings per share growth (CAGR)
-19.33%
What the Analysts think about BioMarin
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
Analyst projections of the future price of BioMarin stock.
Bulls say / Bears say
The FDA has accepted BioMarin’s supplemental New Drug Application seeking full traditional approval of VOXZOGO for children with achondroplasia, advancing its regulatory momentum ahead of a target action date in early 2027 (Zacks).
In June 2026, the European Commission approved PALYNZIQ for adolescents aged 12 and older with phenylketonuria, expanding BioMarin’s enzyme therapy addressable market in Europe (SEC filing).
Full-year 2025 VOXZOGO revenue grew 26% year-over-year to $927 million, demonstrating robust commercial uptake across 55 markets and driving rare disease revenue growth (SEC filing).
The Phase 3 ENERGY 3 trial for BMN 401 in children aged 1–12 with ENPP1 deficiency met only one of two co-primary endpoints, raising doubts about meaningful clinical benefits in the pivotal study (Reuters via Yahoo Finance).
Following the May 2026 pivotal ENERGY 3 readout, BioMarin decided in August 2026 to discontinue development of BMN 401 across all indications, narrowing its enzyme therapy pipeline and reflecting significant sunk R&D costs (SEC filing).
In March 2026, BioMarin halted mid-stage trials of its bone disorder program after several cases of hip joint slipping were reported in patients receiving vosoritide, underscoring emerging safety concerns for its CNP-based therapies (Reuters via Yahoo Finance).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
BioMarin Financial Performance
Revenues and expenses
BioMarin Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioMarin News
AllArticlesVideos
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
MarketBeat3 days ago
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
Benzinga3 weeks ago
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
CNBC1 month ago
Funds containing BioMarin
AllUSDGBPEUR
Fund name | Fund size | $BMRN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.83% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.83% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.36% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.36% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.